Posts by: Catarina Silva, MSc

Catarina Silva, MSc

With over three years of experience in the medical communications business, Catarina holds a BSc. in Biomedical Sciences and a MSc. in Neurosciences. Apart from writing, she has been involved in patient-oriented translational and clinical research.

September 5, 2018

Follicular Lymphoma Patients with Private Insurance in US Show Better Overall Survival Rates Than Others, Study Reports

News

Follicular lymphoma patients in the U.S. with private insurance are about twice as likely to survive their cancer than those without health insurance or covered by public plans like Medicare or ... Read more

September 4, 2018

Penn’s Abramson Cancer Center Added as Second Clinical Trial Site for CPI-613 in T-cell Lymphoma

News

The Abramson Cancer Center at the University of Pennsylvania will serve as a second trial site in the Phase 1 study of CPI-613 for T-cell lymphoma patients, according to Rafael Pharmaceuticals, the drug’s developer. The ... Read more

August 17, 2018August 17, 2018

FDA-Approved Poteligeo for Two Types of Cutaneous T-cell Lymphoma

News

The U.S. Food and Drug Administration’s (FDA) recent approval of Poteligeo (mogamulizumab-kpkc) was based on a Phase 3 trial that showed Poteligeo significantly slowed disease progression in adults with relapsed or ... Read more

August 7, 2018

New Fluorescent Probe Able to Identify, Track Evasive Cancer Stem Cells in Mice, Study Reports

News

Scientists have developed a molecular probe that finds and illuminates cancer stem cells in human cancer cell lines and live mice. The ability to identify and track these elusive cells, ... Read more

October 19, 2017

FDA Approves Yescarta, First CAR T-cell Therapy for Lymphoma

News

The U.S. Food and Drug Administration (FDA) approved Kite Pharma‘s Yescarta (axicabtagene ciloleucel) for the treatment of relapsed or refractory large B-cell lymphoma patients who received at least two prior ... Read more